Swiss Biotech Day 2018
May 1, 2018

Pharmidex will be at the Swiss Biotech day 2018 on the 3rd May 2018

The Pharmidex team, Specfically including Dr Moh Tadayyon, Dr Mo Alavijeh and Dr Chris Ireson will be attending the Swiss Biotech Day in Basel, Switzerland, 3 May 2018.


 

The Swiss Biotech Day has long become the standard annual get-together of the Swiss bio­pharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and pharmaceutical research, development and production, proved to be the ideal location.


The SBD is not just the place to be for members of the Swiss Biotech Association, who traditionally meet there for the association’s Annual General Assembly. As always, the event targets entrepreneurs, investors, researchers, analysts, BD&L, political decision makers, industry stakeholders and media.


This year's event will take place on 3 May 2018 and will bring together more than 600 senior executives from the life science industry across Europe. 

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 30, 2025
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 28, 2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩‍🔬 👨‍🔬 Welcome to the team, Gabrielle and Mohammed!
BATA Taste Aversion
July 24, 2025
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
More Posts